請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78324
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李水盛(Shoei-Sheng Lee) | |
dc.contributor.author | Fu-Chun Hsu | en |
dc.contributor.author | 許富鈞 | zh_TW |
dc.date.accessioned | 2021-07-11T14:51:14Z | - |
dc.date.available | 2023-08-04 | |
dc.date.copyright | 2020-09-10 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-04 | |
dc.identifier.citation | 1. Dalbeth, N.; Choi, H. K.; Joosten, L. A. B.; Khanna, P. P.; Matsuo, H.; Perez-Ruiz, F.; Stamp, L. K., Gout. Nat. Rev. Dis. Primers 2019, 5, ID: 69. 2. Halevy, S.; Ghislain, P. D.; Mockenhaupt, M.; Fagot, J. P.; Bouwes Bavinck, J. N.; Sidoroff, A.; Naldi, L.; Dunant, A.; Viboud, C.; Roujeau, J. C., Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 2008, 58, 25-32. 3. Sattui, S. E.; Gaffo, A. L., Treatment of hyperuricemia in gout: Current therapeutic options, latest developments and clinical implications. Ther. Adv. Musculoskelet. Dis. 2016, 8, 145-159. 4. Tsai, S. F.; Lee, S. S., Neolignans as xanthine oxidase inhibitors from Hyptis rhomboides. Phytochemistry 2014, 101, 121-127. 5. 林義力,香苦草抑制黃嘌呤氧化酶活性成分之研究及花生依原花青素之成分研究。國立臺灣大學藥學專業學院藥學研究所碩士論文,台北 (2016)。 6. Dipiro, J. T.; Talbert, R. L.; Yee, G. C.; Matzke, G. R.; Wells, B. G.; Michael Posey, L., Pharmacotherapy: A Pathophysiologic Approach. 10th ed.; McGraw-Hill Medical: New York, 2017; p 1485-1504. 7. Mehmood, A.; Ishaq, M.; Zhao, L.; Safdar, B.; Rehman, A. U.; Munir, M.; Raza, A.; Nadeem, M.; Iqbal, W.; Wang, C., Natural compounds with xanthine oxidase inhibitory activity: A review. Chem. Biol. Drug Des. 2019, 93, 387-418. 8. Nishino, T.; Okamoto, K., Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J. Biol. Inorg. Chem. 2015, 20, 195-207. 9. Maruhashi, T.; Hisatome, I.; Kihara, Y.; Higashi, Y., Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis 2018, 278, 226-231. 10. Luna, G.; Dolzhenko, A. V.; Mancera, R. L., Inhibitors of xanthine oxidase: Scaffold diversity and structure-based drug design. ChemMedChem 2019, 14, 714-743. 11. Kumar, R.; Darpan; Sharma, S.; Singh, R., Xanthine oxidase inhibitors: A patent survey. Expert Opin. Ther. Pat. 2011, 21, 1071-1108. 12. McNeil, M.; Facey, P.; Porter, R., Essential oils from the Hyptis genus- A review (1909-2009). Nat. Prod. Commun. 2011, 6, 1775-1796. 13. Huang, T. C., Flora of Taiwan. 2 ed.; Taiwan, Taipei, 1996; p 465-468. 14. Takayama, C.; de-Faria, F. M.; de Almeida, A. C.; Valim-Araujo Dde, A.; Rehen, C. S.; Dunder, R. J.; Socca, E. A.; Manzo, L. P.; Rozza, A. L.; Salvador, M. J.; Pellizzon, C. H.; Hiruma-Lima, C. A.; Luiz-Ferreira, A.; Souza-Brito, A. R., Gastroprotective and ulcer healing effects of essential oil from Hyptis spicigera Lam. (Lamiaceae). J. Ethnopharmacol. 2011, 135, 147-155. 15. Simoes, R. R.; Coelho, I. D.; Junqueira, S. C.; Pigatto, G. R.; Salvador, M. J.; Santos, A. R.; de Faria, F. M., Oral treatment with essential oil of Hyptis spicigera Lam. (Lamiaceae) reduces acute pain and inflammation in mice: Potential interactions with transient receptor potential (TRP) ion channels. J. Ethnopharmacol. 2017, 200, 8-15. 16. Fragoso-Serrano, M.; Gonzalez-Chimeo, E.; Pereda-Miranda, R., Novel labdane diterpenes from the insecticidal plant Hyptis spicigera. J. Nat. Prod. 1999, 62, 45-50. 17. Xu, D. H.; Huang, Y. S.; Jiang, D. Q.; Yuan, K., The essential oils chemical compositions and antimicrobial, antioxidant activities and toxicity of three Hyptis species. Pharm. Biol. 2013, 51, 1125-1130. 18. Deng, Y.; Balunas, M. J.; Kim, J.; Lantvit, D. D.; Chin, Y. W.; Chai, H.; Sugiarso, S.; Kardono, L. B. S.; Fong, H. S. S.; Pezzuto, J. M.; Swanson, S. M.; Blanco, E. J. C.; Kinghorn, A. D., Bioactive 5,6-dihydro-α-pyrone derivatives from Hyptis brevipes. J. Nat. Prod. 2009, 72, 1165-1169. 19. Moreira, A. C. P.; Lima, E. O.; Wanderley, P. A.; Carmo, E. S.; Souza, E. L., Chemical composition and antifungal activity of Hyptis suaveolens (L.) Poir leaves. Braz. J. Microbiol. 2010, 41, 28-33. 20. Ghaffari, H.; Ghassam, B. J.; Chandra Nayaka, S.; Ramachandra Kini, K.; Prakash, H. S., Antioxidant and neuroprotective activities of Hyptis suaveolens (L.) Poit. against oxidative stress-induced neurotoxicity. Cell. Mol. Neurobiol. 2014, 34, 323-331. 21. Jesus, N. Z.; Falcao, H. S.; Lima, G. R.; Caldas Filho, M. R.; Sales, I. R.; Gomes, I. F.; Santos, S. G.; Tavares, J. F.; Barbosa-Filho, J. M.; Batista, L. M., Hyptis suaveolens (L.) Poit (Lamiaceae), a medicinal plant protects the stomach against several gastric ulcer models. J. Ethnopharmacol. 2013, 150, 982-988. 22. Bojorquez-Velazquez, E.; Lino-Lopez, G. J.; Huerta-Ocampo, J. A.; Barrera-Pacheco, A.; Barba de la Rosa, A. P.; Moreno, A.; Mancilla-Margalli, N. A.; Osuna-Castro, J. A., Purification and biochemical characterization of 11S globulin from chan (Hyptis suaveolens L. Poit) seeds. Food Chem. 2016, 192, 203-211. 23. Mueller, M.; Cavarkapa, A.; Unger, F. M.; Viernstein, H.; Praznik, W., Prebiotic potential of neutral oligo- and polysaccharides from seed mucilage of Hyptis suaveolens. Food Chem. 2017, 221, 508-514. 24. Praznik, W.; Cavarkapa, A.; Unger, F. M.; Loeppert, R.; Holzer, W.; Viernstein, H.; Mueller, M., Molecular dimensions and structural features of neutral polysaccharides from the seed mucilage of Hyptis suaveolens L. Food Chem. 2017, 221, 1997-2004. 25. Suarez-Ortiz, G. A.; Cerda-Garcia-Rojas, C. M.; Hernandez-Rojas, A.; Pereda-Miranda, R., Absolute configuration and conformational analysis of brevipolides, bioactive 5,6-dihydro-α-pyrones from Hyptis brevipes. J. Nat. Prod. 2013, 76, 72-78. 26. Suarez-Ortiz, G. A.; Cerda-Garcia-Rojas, C. M.; Fragoso-Serrano, M.; Pereda-Miranda, R., Complementarity of DFT calculations, NMR anisotropy, and ECD for the configurational analysis of brevipolides K-O from Hyptis brevipes. J. Nat. Prod. 2017, 80, 181-189. 27. Tang, G.; Liu, X.; Gong, X.; Lin, X.; Lai, X.; Wang, D.; Ji, S., Studies on the chemical compositions of Hyptis suaveolens (L.) Poit. J. Serb. Chem. Soc. 2019, 84, 245-252. 28. Prawatsri, S.; Suksamrarn, A.; Chindaduang, A.; Rukachaisirikul, T., Abietane diterpenes from Hyptis suaveolens. Chem. Biodivers. 2013, 10, 1494-1500. 29. Fun, C. E.; Baerheim Svendsen, A., The essential oil of Hyptis suaveolens Poit. grown on Aruba. Flavour Fragr. J. 1990, 5, 161-163. 30. Conti, B.; Canale, A.; Cioni, P. L.; Flamini, G.; Rifici, A., Hyptis suaveolens and Hyptis spicigera (Lamiaceae) essential oils: qualitative analysis, contact toxicity and repellent activity against Sitophilus granarius (L.) (Coleoptera: Dryophthoridae). J. Pest Sci. 2011, 84, 219-228. 31. Azevedo, N. R.; Campos, I. F. P.; Ferreira, H. D.; Portes, T. A.; Santos, S. C.; Seraphin, J. C.; Paula, J. R.; Ferri, P. H., Chemical variability in the essential oil of Hyptis suaveolens. Phytochemistry 2001, 57, 733-736. 32. Priyadharshini, S. D.; Sujatha, V., Antioxidant and cytotoxic studies on two known compounds isolated from Hyptis suaveolens leaves. Int. J. Pharm. Pharm. Sci. 2013, 5, 283-290. 33. Ngassoum, M. B.; Jirovetz, L.; Buchbamr, G., Essential oil and headspace from Hyptis suaveolens (L.) Poit. leaves and flowers from Cameroon. J. Essent. Oil Res. 1999, 11, 283-288. 34. Arai, M. A.; Uchida, K.; Sadhu, S. K.; Ahmed, F.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M., Hedgehog inhibitors from Artocarpus communis and Hyptis suaveolens. Bioorg. Med. Chem. 2015, 23, 4150-4154. 35. Ziegler, H. L.; Jensen, T. H.; Christensen, J.; Stark, D.; Hagerstrand, H.; Sittie, A. A.; Olsen, C. C.; Staalso, T.; Ekpe, P.; Jaroszewski, J. W., Possible artefacts in the in vitro determination of antimalarial activity of natural products that incorporate into lipid bilayer: apparent antiplasmodial activity of dehydroabietinol, a constituent of Hyptis suaveolens. Planta Med. 2002, 68, 547-549. 36. Misra, T. N.; Singh, R. S.; Upadhyay, J., A natural triterpene acid from Hyptis suaveolens. Phytochemistry 1983, 22, 2557-2558. 37. Lopez-Vallejo, F.; Fragoso-Serrano, M.; Suarez-Ortiz, G. A.; Hernandez-Rojas, A. C.; Cerda-Garcia-Rojas, C. M.; Pereda-Miranda, R., Vicinal 1H-1H NMR coupling constants from density functional theory as reliable tools for stereochemical analysis of highly flexible multichiral center molecules. J. Org. Chem. 2011, 76, 6057-6066. 38. Sprogoe, K.; Stark, D.; Jager, A. K.; Adsersen, A.; Hansen, S. H.; Witt, M.; Landbo, A. R.; Meyer, A. S.; Jaroszewski, J. W., Targeted natural product isolation guided by HPLC–SPE–NMR: constituents of Hubertia species. J. Nat. Prod. 2007, 70, 1472-1477. 39. Chen, C. K.; Kang, J. J.; Wen, W. C.; Chiang, H. F.; Lee, S. S., Metabolites of antroquinonol found in rat urine following oral administration. J. Nat. Prod. 2014, 77, 1061-1064. 40. Lin, H. C.; Lee, S. S., Dibenzocycloheptanoids from the leaves of Cinnamomum subavenium. J. Nat. Prod. 2012, 75, 1735-1743. 41. Kovacs, H.; Moskau, D.; Spraul, M., Cryogenically cooled probes—a leap in NMR technology. Prog. Nucl. Magn. Reson. Spectrosc. 2005, 46, 131-155. 42. Li, H.; Zhang, Y.; Liu, Q.; Sun, C.; Li, J.; Yang, P.; Wang, X., Preparative separation of phenolic compounds from Chimonanthus praecox flowers by high-speed counter-current chromatography using a stepwise elution mode. Molecules 2016, 21, 1016-1025. 43. Wang, D.; Mu, Y.; Dong, H.; Yan, H.; Hao, C.; Wang, X.; Zhang, L., Chemical constituents of the ethyl acetate extract from Diaphragma juglandis fructus and their inhibitory activity on nitric oxide production in vitro. Molecules 2017, 23, 72-83. 44. Ding, H. Y.; Lin, H. C.; Teng, C. M.; Wu, Y. C., Phytochemical and pharmacological studies on Chinese Paeonia species. J. Chin. Chem. Soc. 2000, 47, 381-388. 45. Iqbal, K.; Iqbal, J.; Staerk, D.; Kongstad, K. T., Characterization of antileishmanial compounds from Lawsonia inermis L. leaves using semi-high resolution antileishmanial profiling combined with HPLC-HRMS-SPE-NMR. Front. Pharmacol. 2017, 8, 337. 46. Ito, S.; Yamanaka, Y.; Ojika, M.; Wakamatsu, K., The metabolic fate of ortho-quinones derived from catecholamine metabolites. Int. J. Mol. Sci. 2016, 17, 164-173. 47. Gruber, G.; Kerschensteiner, L.; Steglich, W., Chromapedic acid, pulvinic acids and acetophenone derivatives from the mushroom Leccinum chromapes (Boletales). Z. Naturforsch. 2014, 69b, 432-438. 48. Huang, A. C.; Wilde, A.; Ebmeyer, J.; Skouroumounis, G. K.; Taylor, D. K., Examination of the phenolic profile and antioxidant activity of the leaves of the Australian native plant Smilax glyciphylla. J. Nat. Prod. 2013, 76, 1930-1936. 49. Matsuura, H.; Amano, M.; Kawabata, J.; Mizutani, J., Isolation and measurement of quercetin glucosides in flower buds of Japanese butterbur (Petasites japonicus subsp. gigantea Kitam.). Biosci. Biotechnol. Biochem. 2002, 66, 1571-1575. 50. Refaat, J.; Samy, M. N.; Desoukey, S. Y.; Ramadan, M. A.; Sugimoto, S.; Matsunami, K.; Kamel, M. S., Chemical constituents from Chorisia chodatii flowers and their biological activities. Med. Chem. Res. 2015, 24, 2939-2949. 51. Hendra, R.; Keller, P. A., Phytochemical studies on two Australian Anigozanthos plant species. J. Nat. Prod. 2017, 80, 2141-2145. 52. Kim, A. R.; Jin, Q.; Jin, H. G.; Ko, H. J.; Woo, E. R., Phenolic compounds with IL-6 inhibitory activity from Aster yomena. Arch. Pharm. Res. 2014, 37, 845-851. 53. Ha, T. J.; Lee, J. H.; Lee, M. H.; Lee, B. W.; Kwon, H. S.; Park, C. H.; Shim, K. B.; Kim, H. T.; Baek, I. Y.; Jang, D. S., Isolation and identification of phenolic compounds from the seeds of Perilla frutescens (L.) and their inhibitory activities against α-glucosidase and aldose reductase. Food Chem. 2012, 135, 1397-1403. 54. Al-Musayeib, N.; Perveen, S.; Fatima, I.; Nasir, M.; Hussain, A., Antioxidant, anti-glycation and anti-inflammatory activities of phenolic constituents from Cordia sinensis. Molecules 2011, 16, 10214-10226. 55. Dastmalchi, K.; Ollilainen, V.; Lackman, P.; Boije af Gennas, G.; Dorman, H. J.; Jarvinen, P. P.; Yli-Kauhaluoma, J.; Hiltunen, R., Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg. Med. Chem. 2009, 17, 867-871. 56. Lu, Y.; Foo, L. Y.; Wong, H., Sagecoumarin, a novel caffeic acid trimer from Salvia officinalis. Phytochemistry 1999, 52, 1149-1152. 57. Murata, T.; Watahiki, M.; Tanaka, Y.; Miyase, T.; Yoshizaki, F., Hyaluronidase inhibitors from Takuran, Lycopus lucidus. Chem. Pharm. Bull. 2010, 58, 394-397. 58. Agata, I.; Kusakabe, H.; Hatano, T.; Nishibe, S.; Okuda, T., Melitric acids A and B, new trimeric caffeic acid derivatives from Melissa officinalis. Chem. Pharm. Bull. 1993, 41, 1608-1611. 59. Murata, T.; Oyama, K.; Fujiyama, M.; Oobayashi, B.; Umehara, K.; Miyase, T.; Yoshizaki, F., Diastereomers of lithospermic acid and lithospermic acid B from Monarda fistulosa and Lithospermum erythrorhizon. Fitoterapia 2013, 91, 51-59. 60. Koukoulitsa, C.; Zika, C.; Geromichalos, G. D.; Demopoulos, V. J.; Skaltsa, H., Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum. Bioorg. Med. Chem. 2006, 14, 1653-1659. 61. Ly, T. N.; Shimoyamada, M.; R., Y., Isolation and characterization of rosmarinic acid oligomers in Celastrus hindsii Benth. leaves and their antioxidative activity. J. Agric. Food Chem. 2006, 54, 3786-3793. 62. Wu, Z. J.; OuYang, M. A.; Yang, C. R., Polyphenolic constituents of Salvia przewalskii. Acta Botanica Yunnanica 1999, 21, 512-516. 63. Murata, T.; Miyase, T.; Yoshizaki, F., Hyaluronidase inhibitors from Keiskea japonica. Chem. Pharm. Bull. 2012, 60, 121-128. 64. Lu, Y.; Foo, L. Y., Rosmarinic acid derivatives from Salvia officinalis. Phytochemistry 1999, 51, 91-94. 65. Dini, I.; Tenore, G. C.; Dini, A., New polyphenol derivative in Ipomoea batatas tubers and its antioxidant activity. J. Agric. Food Chem. 2006, 54, 8733-8737. 66. Pantoja Pulido, K. D.; Colmenares Dulcey, A. J.; Isaza Martinez, J. H., New caffeic acid derivative from Tithonia diversifolia (Hemsl.) A. Gray butanolic extract and its antioxidant activity. Food Chem. Toxicol. 2017, 109, 1079-1085. 67. Znati, M.; Ben Jannet, H.; Cazaux, S.; Souchard, J. P.; Harzallah Skhiri, F.; Bouajila, J., Antioxidant, 5-lipoxygenase inhibitory and cytotoxic activities of compounds isolated from the Ferula lutea flowers. Molecules 2014, 19, 16959-16975. 68. Ono, M.; Kasuoka, C.; Odake, Y.; Ikegashira, S.; Ito, Y.; Nohara, T., Antioxidative constituents from Tessaria integrifolia. Food Sci. Technol. Res. 2000, 6, 106-114. 69. Clifford, M. N.; Johnston, K. L.; Knight, S.; Kuhnert, N., Hierarchical scheme for LC-MSn identification of chlorogenic acids. J. Agric. Food Chem. 2003, 51, 2900-2911. 70. Han, J.; Ye, M.; Qiao, X.; Xu, M.; Wang, B. R.; Guo, D. A., Characterization of phenolic compounds in the Chinese herbal drug Artemisia annua by liquid chromatography coupled to electrospray ionization mass spectrometry. J. Pharm. Biomed. Anal. 2008, 47, 516-525. 71. Jaiswal, R.; Deshpande, S.; Kuhnert, N., Profiling the chlorogenic acids of Rudbeckia hirta, Helianthus tuberosus, Carlina acaulis and Symphyotrichum novae-angliae leaves by LC-MS(n). Phytochem. Anal. 2011, 22, 432-441. 72. Tung, N. H.; Uto, T.; Morinaga, O.; Shoyama, Y., Chemical constituents from the aerial parts of Bupleurum falcatum L. and biological evidences. Nat. Prod. Sci. 2015, 21, 71-75. 73. Nguyen, M. T.; Awale, S.; Tezuka, Y.; Ueda, J. Y.; Tran, Q. L.; Kadota, S., Xanthine oxidase inhibitors from the flowers of Chrysanthemum sinense. Planta Med. 2006, 72, 46-51. 74. Zhong, J. D.; Feng, Y.; Li, H. M.; Xia, X. S.; Li, R. T., A new flavonoid glycoside from Elsholtzia bodinieri. Nat. Prod. Res. 2016, 30, 2278-2284. 75. Wu, X.; Gao, H.; Sun, W.; Yu, J.; Hu, H.; Xu, Q.; Chen, X., Nepetoidin B, a natural product, inhibits LPS-stimulated nitric oxide production via modulation of iNOS mediated by NF-κB/MKP-5 pathways. Phytother. Res. 2017, 31, 1072-1077. 76. Kim, G. D.; Park, Y. S.; Jin, Y. H.; Park, C. S., Production and applications of rosmarinic acid and structurally related compounds. Appl. Microbiol. Biotechnol. 2015, 99, 2083-2092. 77. Grayer, R. J.; Eckert, M. R.; Veitch, N. C.; Kite, G. C.; Marin, P. D.; Kokubun, T.; Simmonds, M. S. J.; Paton, A. J., The chemotaxonomic significance of two bioactive caffeic acid esters, nepetoidins A and B, in the Lamiaceae. Phytochemistry 2003, 64, 519-528. 78. Kang, E. S.; Lee, G. T.; Kim, B. S.; Kim, C. H.; Seo, G. H.; Han, S. J.; Hur, K. Y.; Ahn, C. W.; Ha, H.; Jung, M.; Ahn, Y. S.; Cha, B. S.; Lee, H. C., Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats. Eur. J. Pharmacol. 2008, 579, 418-425. 79. Lawal, U.; Shaari, K.; Ismail, I. S.; Khatib, A.; Abas, F., Antioxidant and α-glucosidase inhibitory activities of isolated compounds from Ipomoea aquatica. Rec. Nat. Prod. 2016, 10, 701-707. 80. Liu, J.; Nakamura, S.; Zhuang, Y.; Yoshikkawa, M.; Hiussein, G. M. E.; Matsuo, K.; Matsuda, H., Medicinal flowers. XXXX. Structures of dihydroisocoumarin glycosides and inhibitory effects on aldose reducatase from the flowers of Hydrangea macrophylla var. thunbergii. Chem. Pharm. Bull. 2013, 61, 655-661. 81. Mishima, S.; Yoshida, C.; Akino, S.; Sakamoto, T., Antihypertensive effects of Brazilian propolis: Identification of caffeoylquinic acids as constituents involved in the hypotension in spontaneously hypertensive rats. Biol. Pharm. Bull. 2005, 28, 1909-1914. 82. Satake, T.; Kamiya, K.; An, Y.; Oishi, T.; Yamamoto, J., The anti-thrombotic active constituents from Centella asiatica. Biol. Pharm. Bull. 2007, 30, 935-940. 83. Satake, T.; Kamiya, K.; Saiki, Y.; Hama, T.; Fujimoto, Y.; Kitanaka, S.; Kimura, Y.; Uzawa, J.; Endang, H.; Umar, M., Studies on the constituents of fruits of Helicteres isora L. Chem. Pharm. Bull. 1999, 47, 1444-1447. 84. Zhu, X. F.; Zhang, H. X.; Lo, R., Three di-O-caffeoylquinic acid derivatives from the heads of Cynara scolymus L. Nat. Prod. Res. 2009, 23, 527-532. 85. Masters, C. L.; Bateman, R.; Blennow, K.; Rowe, C. C.; Sperling, R. A.; Cummings, J. L., Alzheimer's disease. Nat. Rev. Dis. Primers 2015, 1, ID: 15056. 86. Liu, J.; Chang, L.; Song, Y.; Li, H.; Wu, Y., The role of NMDA receptors in Alzheimer's disease. Front. Neurosci. 2019, 13, 43. 87. Houghton, P. J.; Ren, Y.; Howes, M. J., Acetylcholinesterase inhibitors from plants and fungi. Nat. Prod. Rep. 2006, 23, 181-199. 88. McHardy, S. F.; Wang, H. L.; McCowen, S. V.; Valdez, M. C., Recent advances in acetylcholinesterase inhibitors and reactivators: an update on the patent literature (2012-2015). Expert Opin. Ther. Pat. 2017, 27, 455-476. 89. Mukherjee, P. K.; Kumar, V.; Mal, M.; Houghton, P. J., Acetylcholinesterase inhibitors from plants. Phytomedicine 2007, 14, 289-300. 90. Chiou, C. M.; Kang, J. J.; Lee, S. S., Litebamine N-homologues preparation and anti-acetylcholinesterase activity. J. Nat. Prod. 1998, 61, 46-50. 91. 林敬婷,Boldine及litebamine衍生物之製備與生物活性研究。國立臺灣大學醫學院藥學研究所碩士論文,台北 (2007)。 92. 林敬婷,第一部分:TM-1-1磷酸酯衍生物之製備;第二部分:N-烷基苯-2-萘醯胺化合物之製備與其抗黃嘌呤氧化酶抑制之研究;第三部分:改良型鈀碳催化氫解反應於酚性生物鹼去酚基反應之研究。國立臺灣大學藥學專業學院藥學研究所博士論文,台北 (2016)。 93. Lee, S. S.; Chiou, C. M.; Lin, H. Y.; Chen, C. H., Preparation of phenanthrene alkaloids via solvolysis of 2-hydroxyaporphines. Tetrahedron Letters 1995, 36, 1531-1532. 94. Lee, S. S.; Lin, C. Y.; Chen, C. H., Cleavage of (-)-eschscholtzine with sodium in liquid-ammonia. J. Chin. Chem. Soc. 1991, 38, 389-391. 95. Ayer, W. A.; Taylor, W. I., The conversion of bulbocapnine into morphothebaine. J. Chem. Soc. 1956, 472. 96. Azzena, U.; Dettori, G.; Idini, M. V.; Pisano, L.; Sechi, G., Regioselective reductive demethoxylation of 3,4,5-trimethoxystilbenes. Tetrahedron 2003, 59, 7961-7966. 97. Mori, A.; Mizusaki, T.; Ikawa, T.; Maegawa, T.; Monguchi, Y.; Sajiki, H., Mechanistic study of a Pd/C-catalyzed reduction of aryl sulfonates using the Mg-MeOH-NH4OAc system. Chemistry 2007, 13, 1432-1441. 98. Lin, C. T.; Lee, S. S., Deoxygenation of phenolic alkaloids by a modified Pd/C-catalyzed hydrogenolysis method. Synthesis 2015, 47, 2586-2592. 99. 邱繼明,Litebamine,thaliporphine及caryachine衍生物之製備與生物活性的研究。國立臺灣大學醫學院藥學研究所博士論文,台北 (1997)。 100. White, E. H., The chemistry of the N-alkyl-N-nitrosoamides. I. Methods of preparation. J. Am. Chem. Soc. 1955, 77, 6008-6010. 101. White, E. H., The chemistry of the N-alkyl-N-nitrosoamides. II. A new method for the deamination of aliphatic amines. J. Am. Chem. Soc. 1955, 77, 6011-6014. 102. White, E. H., The chemistry of the N-alkyl-N-nitrosoamides. III. Mechanism of the nitrogen elimination reaction. J. Am. Chem. Soc. 1955, 77, 6014-6022. 103. Chen, Y.; Romaire, J. P.; Newhouse, T. R., Palladium-catalyzed α,β-dehydrogenation of esters and nitriles. J. Am. Chem. Soc. 2015, 137, 5875-5878. 104. Bartholomew, C. H., Mechanisms of catalyst deactivation. Appl. Catal. A-Gen. 2001, 212, 17-60. 105. Garcia-Granados, A.; Lopez, P. E.; Melguizo, E.; Parra, A.; Simeo, Y., Remote hydroxylation of methyl groups by regioselective cyclopalladation partial synthesis of hyptatic acid A. J. Org. Chem. 2007, 72, 3500-3509. 106. Sahali, Y.; Skipper, P. L.; Tannenbaum, S. R., New syntheses of cyclopenta[cd]pyrene 3,4-oxide and 4-pyrenylacetic acid. J. Org. Chem. 1990, 55, 2918-2920. 107. Walborsky, H. M.; David, R. H.; Howton, D. R., A total synthesis of linoleic acid. J. Am. Chem. Soc. 1951, 73, 2590-2594. 108. Hermant, P.; Bosc, D.; Piveteau, C.; Gealageas, R.; Lam, B.; Ronco, C.; Roignant, M.; Tolojanahary, H.; Jean, L.; Renard, P. Y.; Lemdani, M.; Bourotte, M.; Herledan, A.; Bedart, C.; Biela, A.; Leroux, F.; Deprez, B.; Deprez-Poulain, R., Controlling plasma stability of hydroxamic acids: A MedChem toolbox. J. Med. Chem. 2017, 60, 9067-9089. 109. Moffatt, J. G., Cholane-24-al. Organic Syntheses 1967, 47. 110. Coskun, N., Mild and efficient method for the synthesis of nitriles. Synth. Commun. 2004, 34, 1625-1630. 111. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95. 112. Rhee, I. K.; Meent, M.; Ingkaninan, K.; Verpoorte, R., Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining. J. Chromatogr. A 2001, 915, 217-223. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78324 | - |
dc.description.abstract | 本論文包含兩個部分: 第一部分:穗花香苦草、短柄香苦草及香苦草種子化學成分之研究 臨床上常使用黃嘌呤氧化酶抑制劑於預防痛風復發,但目前常用的抑制劑-allopurinol-有引發嚴重過敏反應之可能,因此仍須開發具低副作用的抑制劑。本實驗室過去自頭花香苦草 (Hyptis rhomboides) 地上部及香苦草 (H. suaveolens) 莖部發現具有抑制黃嘌呤氧化酶的成分。因此本研究旨在運用高效液相層析-固相萃取-細管轉移-核磁共振儀串聯技術 (HPLC-SPE-TT-NMR),分析同為香苦草屬的穗花香苦草 (H. spicigera)、短柄香苦草 (H. brevipes) 及香苦草種子 (山粉圓) 是否含有抑制黃嘌呤氧化酶的成分,並期望賦予山粉圓更高的應用價值。 穗花香苦草葉部、短柄香苦草地上部及香苦草種子之乙醇萃取物,分別經液相-液相分配進行極性分割後,取乙酸乙酯與正丁醇可溶部分,經Sephadex LH-20 column分群,再運用HPLC-SPE-TT-NMR及HPLC-MS進行分離與分析,自穗花香苦草葉部鑑定出2個酚類成分 (1及2)、4個黃酮類成分 (4、5、17及18) 與12個苯丙烷類成分 (3及6-16),其中,sagecoumarin methyl ester (13) 為一新化合物;自短柄香苦草地上部鑑定出1個酚類成分 (1)、3個黃酮類成分 (4、24及25) 與10個苯丙烷類成分 (3、6、7、10、12及19-23),其中,shimobashiric acid C (19)、lithospermic acid B (20) 及其甲酯化衍生物 (21及22) 為四聚體苯丙烷類,此為首次自香苦草屬植物中發現;最後,自香苦草種子鑑定出6個酚類成分 (3、26-29及38) 與9個苯丙烷類成分 (3及30-37),與過去自其莖部發現之成分差異極大,且化合物30-37為dicaffeoylquinic acid類成分。透過定量實驗揭示香苦草種子富含dicaffeoylquinic acid類成分,且於黃嘌呤氧化酶抑制試驗呈現中等抑制效果 (30、31、35及37),可見其具有保健食品之應用價值。 第二部分:Aporphine及phenanthrene衍生物之製備暨其抗乙醯膽鹼酶與黃嘌呤氧化酶之探討 乙醯膽鹼酶抑制劑常用於改善阿茲海默症的認知及行為功能異常之症狀。本實驗室過去發現litebamine (40) 具有抑制乙醯膽鹼酶 (AChE) 之效果,其結構上N原子與4號位置之O原子間之距離與乙醯膽鹼接近,使得4-OMe被認為是重要的藥效基團。然而,進一步移除aporphine衍生物之2-OH,維持1-OH或-OMe;或移除litebamine之3-OH,維持4-OH或-OMe (43-47) 卻導致抑制活性下降。因此本研究旨在製備去除1-OMe且保留2-OH或-OMe之aporphine衍生物 (50-52), 及保留3-OH且去除4-OMe之litebamine衍生物 (54及56),繼續探討其活性。其中,以化合物56具有最佳的抗AChE活性 (IC50 6.3 μM c.f. galantamine 1.1 μM)。本研究結果釐清此類結構之結構與活性關係,以aporphine衍生物2號及litebamine衍生物3號位置的氧原子對於AChE抑制活性較為重要;此外,litebamine衍生物之6-OMe亦為重要基團,此結果將有助於開發衍自此類生物鹼之AChE抑制劑。 另一方面,本實驗室之阿朴芬類生物鹼於電腦分子模擬中與黃嘌呤氧化酶的結合力佳,但與實際酵素測試結果並不相符,推測可能是模擬時胺基自動質子化,而與酵素產生離子鍵,但實測時 (pH 7.5) 質子化卻未發生有關。本研究為探討此效應,以台灣雅楠富含之生物鹼laurolitsine為起始物,製備含四級銨之phenanthrene衍生物74;此外,亦同時製備含羥基 (68、80及96) 及羧基 (76及93) 之衍生物,並進行黃嘌呤氧化酶抑制實驗以評估其抑制效果。然而,具四級銨之目標產物74於100 μg/mL之濃度下僅達18%抑制率,無法有效提供離子鍵作用力。因此,此類阿朴芬生物鹼於電腦分子模擬與實際酵素實驗結果不符之原因尚需進一步研究釐清。 | zh_TW |
dc.description.abstract | Part 1. Chemical investigation of Hyptis spicigera, H. brevipes, and the seed of H. suaveolens Xanthine oxidase inhibitors are used in clinic to prevent recurrent gout. As some severe side effects of allopurinol, a common xanthine oxidase inhibitor, were reported, the discovery of safer xanthine oxidase inhibitors is still in medical need. Several unusual phenylpropanoids had been isolated from the aerial part of H. rhomboides and the stem of H. suaveolens from our lab. They displayed good inhibitory activity against xanthine oxidase. Whether Hyptis spicigera, H. brevipes, and the seed of H. suaveolens (san fen yuan) from the same genus contain similar chemical constituents is the aim of current study. Our efforts led to the identification of 18 compounds (1-18) from the ethanol extract of H. spicigera leaves, 14 (1, 3, 4, 6, 7, 10, 12, and 19-25) from H. brevipes aerial parts, and 15 (3, and 26-38) from H. suaveolens seeds by separation and analysis through liquid-liquid partitioning, Sephadex LH-20 chromatography, and HPLC-SPE-TT-NMR and HPLC-MS analyses. Among these isolates, sagecoumarin methyl ester (13) is new and four known, i.e. shimobashiric acid C (19), lithospermic acid B (20), lithospermic acid B 9''-methyl ester (21), and lithospermic acid B 9'''-methyl ester (22), were firstly reported tetrameric phenylpropanoids from Hyptis plants. Besides, H. suaveolens seed is abundant in dicaffeoylquinic acids (30, 31, 35, and 37) which displayed moderate inhibitory activity against xanthine oxidase, determined by quantitative reverse-phase HPLC analysis. Thus, this discovery demonstrated the potential of H. suaveolens seed as nutraceutical. Part 2. Preparation of aporphine and phenanthrene derivatives as acetylcholinesterase inhibitors and xanthine oxidase inhibitors Acetylcholinesterase inhibitors are able to improve the cognitive and behavioral abnormalities of Alzheimer’s disease. Litebamine (40) was demonstrated to possess good inhibitory activity against acetylcholinesterase (AChE) previously. The distance between N and O4 atoms of litebamine was close to that of the corresponding ones in acetylcholine. Thus, this structure moiety was considered to be the pharmacophore. However, aporphines with 1-OH or -OMe but without 2-OH, and litebamines with 4-OH or -OMe but without 3-OH (43-47) were demonstrated poor AChE inhibitory activity by a lab colleague previously. In this study, aporphine derivatives without 1-OMe but with 2-OH or -OMe (50-52), and litetamine derivatives without 4-OMe but with 3-OH (54 and 56) were prepared to verify their anti-AChE activity furtherly. Among these derivatives, 56 displayed the best anti-AChE activity (IC50 6.3 μM c.f. galantamine 1.1 μM). This study discloses partial structure–activity relationship of aporphine and litebamine derivatives. The O2 of aporphine and O3 of litebamine skeletons are essential to possess AChE inhibitory activity, in contrast to that suggested before, i.e. O4. Besides, the 6-OMe substitution of litebamine derivatives was found essential as well. The current result provides useful information for the exploration of AChE inhibitors derived from these alkaloids. Several aporphine alkaloids have been demonstrated good docking scores by molecular docking, which, however, did not correlate well with their inhibitory activity against xanthine oxidase. The nitrogen atom of these aporphines was automatically protonated during docking study, providing additional ionic interaction to the binding. This phenomenon, however, might not occur under the bioassay condition (pH 7.5). To clarify whether such effect is the main cause of inconsistency between bioassay and molecular docking, this study is aimed to prepare phenanthrene derivatives from laurolitsine with either inherent ammonium (74), or hydroxy (68, 80, and 96), or carboxylic (76 and 93) group in the side chain. Unfortunately, the target compound 74 possessing the inherent quaternary ammonium group didn’t possess good inhibitory activity against xanthine oxidase (18% inhibition at 100 μg/mL). In conclusion, the current study could not verify the initial assumption and such issue remains to be clarified. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:51:14Z (GMT). No. of bitstreams: 1 U0001-0408202014112800.pdf: 16576362 bytes, checksum: 675c9a6ba7523be8d22c73ec571edafb (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 第一部分:穗花香苦草、短柄香苦草及香苦草種子化學成分之研究 1 1. 緒論 1 1.1 研究目的 1 1.2 痛風 2 1.3 黃嘌呤氧化酶及其抑制劑 3 1.3.1 黃嘌呤氧化酶 3 1.3.2 黃嘌呤氧化酶抑制劑 4 1.4 香苦草屬 (Hyptis) 7 1.4.1 穗花香苦草之簡介 7 1.4.2 短柄香苦草之簡介 7 1.4.3 香苦草之簡介 8 1.4.4 香苦草屬 (Hyptis) 植物成分之文獻回顧 10 1.5 高效液相層析-固相萃取-細管轉移-核磁共振儀串聯技術 21 2. 實驗結果與討論 23 2.1 穗花香苦草葉部之成分 23 2.2 短柄香苦草地上部之成分 25 2.3 香苦草種子之成分 27 2.4 化合物1-38之結構解析 28 2.4.1 酚類 (Phenolics) 成分 28 2.4.1.1 3,4-Dihydroxybenzaldehyde (1)、3,4-dihydroxybenzoic acid (27)、4-hydroxybenzoic acid (28) 和isovanillic acid (38) 之結構解析 28 2.4.1.2 Phloracetophenone 2'-O-β-glucopyranoside (2) 之結構解析 30 2.4.1.3 1-(3,4-Dihydroxyphenyl)-ethanone-2-ol (26) 和3',4'-dihydroxyacetophenone (29) 之結構解析 31 2.4.2 黃酮類 (Flavonoids) 成分 33 2.4.2.1 Quercetin 3-O-β-glucopyranoside (4) 和quercetin 3-O-β-(6-O-acetyl)-glucopyranoside (17) 之結構解析 33 2.4.2.2 Kaempferol 3-O-β-glucopyranoside (5) 和kaempferol 3-O-β-(6-O-acetyl)-glucopyranoside (18) 之結構解析 35 2.4.2.3 Quercetin 3-O-β-rutinoside (24) 和kaempferol 3-O-β-rutinoside (25) 之結構解析 37 2.4.3 苯丙烷類 (Phenylpropanoids) 成分 39 2.4.3.1 Caffeic acid (3) 之結構解析 39 2.4.3.2 trans-Rosmarinic acid (6)、methyl rosmarinate (7) 和cis-rosmarinic acid (16) 之結構解析 40 2.4.3.3 Nepetoidin B (12) 和nepetoidin A (23) 之結構解析 43 2.4.3.4 Methyl melitrate A (8)、melitric acid A (10)、9'-O-methyl melitrate A (11) 和dimethyl melitrate A (15) 之結構解析 45 2.4.3.5 Melitric acid B (14) 之結構解析 50 2.4.3.6 Sagecoumarin (9) 和sagecoumarin methyl ester (13) 之結構解析 52 2.4.3.7 Lithospermic acid B (20)、lithospermic acid B 9''-methyl ester (21) 和lithospermic acid B 9'''-methyl ester (22) 之結構解析 54 2.4.3.8 Shimobashiric acid C (19) 之結構解析 58 2.4.3.9 Sodium 3,4-Dicaffeoylquinic acid (30)、sodium 3,5-dicaffeoylquinic acid (31)、methyl 3,5-dicaffeoylquinate (35)、methyl 3,4-dicaffeoylquinate (36) 和sodium 4,5-dicaffeoylquinic acid (37) 之結構解析 60 2.4.3.10 3-O-Caffeoyl-5-O-p-coumaroylquinic acid (32)、3-O-feruloyl-5-O-caffeoylquinic acid (33) 和3-O-caffeoyl-5-O-feruloylquinic acid (34) 之結構解析 65 2.5 香苦草種子95%乙醇萃取物主要成分初步定量實驗 69 2.6 黃嘌呤氧化酶抑制活性測試結果 70 2.7 討論 72 3. 實驗部分 74 3.1 儀器與材料 74 3.1.1 理化性質測定儀器 74 3.1.2 成分分離之儀器與材料 74 3.1.3 試劑與溶媒 76 3.1.4 黃嘌呤氧化酶抑制活性試驗所用試劑與儀器 76 3.2 植物來源 78 3.3 穗花香苦草葉部成分萃取與純化 78 3.3.1 穗花香苦草葉部之萃取 78 3.3.2 穗花香苦草葉部乙酸乙酯可溶部分之分離 79 3.3.2.1 Fr. E2之HPLC-SPE-TT-NMR分析 79 3.3.2.2 Fr. E3之HPLC-SPE-TT-NMR分析 80 3.3.2.3 化合物6、8及9之分離 81 3.3.2.4 Fr. E6-5之HPLC-SPE-TT-NMR分析與半製備級分離 81 3.3.3 穗花香苦草葉部正丁醇可溶部分之分離 83 3.3.3.1 Fr. B6之HPLC-SPE-TT-NMR分析 83 3.4 短柄香苦草地上部成分萃取與純化 86 3.4.1 短柄香苦草地上部之萃取 86 3.4.2 短柄香苦草地上部乙酸乙酯可溶部分之分離 86 3.4.2.1 Frs. E2~E6之HPLC-DAD-MS分析比對 86 3.4.2.2 Fr. E3之分離與HPLC-SPE-TT-NMR分析 87 3.4.2.3 Fr. E5之分離與HPLC-SPE-TT-NMR分析 88 3.4.2.4 Fr. E6之分離與HPLC-SPE-TT-NMR分析 90 3.4.3 短柄香苦草地上部正丁醇可溶部分之分離 94 3.4.3.1 Fr. B4之HPLC-SPE-TT-NMR分析 94 3.4.3.2 Frs. B5之HPLC-DAD-MS分析比對 95 3.5 香苦草種子成分萃取與純化 97 3.5.1 香苦草種子之萃取 97 3.5.2 香苦草種子乙酸乙酯可溶部分之分離 97 3.5.2.1 Fr. E3之HPLC-SPE-TT-NMR分析 98 3.5.2.2 Fr. E4之HPLC-SPE-TT-NMR分析 99 3.5.2.3 化合物30、31、35及36之分離 101 3.5.3 香苦草種子正丁醇可溶部分之分離 101 3.5.3.1 Fr. B5之HPLC-SPE-TT-NMR分析 101 3.6 香苦草種子95%乙醇萃取物主要成分初步定量實驗 104 3.7 化合物之物理數據 106 3.8 黃嘌呤氧化酶抑制活性試驗 115 3.8.1 原理 115 3.8.2 實驗方法 115 3.8.2.1 試劑配製 115 3.8.2.2 實驗步驟 116 3.8.2.3 IC50之計算 117 第二部分:Aporphine及phenanthrene衍生物之製備暨其抗乙醯膽鹼酶與黃嘌呤氧化酶之探討 118 1. 緒論及研究目的 118 1.1 Aporphine及litebamine衍生物之抗乙醯膽鹼酶活性探討 118 1.1.1 阿茲海默症之成因與治療 118 1.1.2 乙醯膽鹼酶及其抑制劑 119 1.1.3 研究目的 122 1.2 Phenanthrene衍生物之抗黃嘌呤氧化酶活性探討 124 1.2.1 黃嘌呤氧化酶及其抑制劑 124 1.2.2 研究目的 124 2. 實驗結果與討論 128 2.1 Litebamine (40) 之製備 128 2.2 A系列化合物之製備 129 2.3 B系列化合物之製備 131 2.4 C系列化合物之製備 134 2.4.1 目標化合物68之製備 134 2.4.2 目標化合物74之製備 137 2.4.3 目標化合物76之製備 139 2.4.4 目標化合物93及96之製備 144 2.5 藥物活性測試 146 2.5.1 乙醯膽鹼酶抑制活性測試結果 146 2.5.2 黃嘌呤氧化酶抑制活性測試結果 149 3. 結論 150 3.1 Aporphine與litebamine衍生物之抗乙醯膽鹼酶活性探討 150 3.2 Phenanthrene衍生物之抗黃嘌呤氧化酶活性探討 151 4. 實驗方法 152 4.1 儀器與材料 152 4.1.1 理化性質測定儀器 152 4.1.2 化合物合成、純化使用之材料、溶劑與試藥 152 4.1.3 高壓反應器 154 4.1.4 乙醯膽鹼酶抑制活性試驗所用試劑與儀器 154 4.2 化合物之製備 155 4.2.1 Litebamine (40) 之製備 155 4.2.1.1 Secoboldine (49) 之製備 155 4.2.1.2 Litebamine (40) 之製備 155 4.2.2 A系列化合物之製備 156 4.2.2.1 2,10-Dimethoxyaporphine (50) 與2-hydroxy-10-methoxyaporphine (51) 之製備 156 4.2.2.2 2,10-Dihydroxyaporphine (52) 之製備 158 4.2.2.3 3,6-Dihydroxysecoaporphine (53) 之製備 159 4.2.2.4 4-Demethoxy-6-O-demethyl-7-dehydroxylitebamine (54) 之製備 159 4.2.2.5 3-Hydroxy-6-methoxysecoaporphine (55) 之製備 161 4.2.2.6 4-Demethoxy-7-dehydroxylitebamine (56) 之製備 161 4.2.3 B系列化合物之製備 162 4.2.3.1 3,6-O,O-Di(1-phenyl-1H-tetrazol-5-yl)-4-demethoxy-7-dehydroxylitebamine (57) 之製備 162 4.2.3.2 3,7-Didehydroxy-4,6-didemethoxy-9,10-dihydrolitebamine (58) 之製備 163 4.2.3.3 3-O-(1-Phenyl-1H-tetrazol-5-yl)-4-demethoxy-7-dehydroxylitebamine (59) 之製備 165 4.2.3.4 3,7-Didehydroxy-4-demethoxy-9,10-dihydrolitebamine (60) 之製備 166 4.2.4 C系列化合物之製備 167 4.2.4.1 N-Acetyllaurolitsine (61) 之製備 167 4.2.4.2 N-Acetylsecolaurolitsine (62) 之製備 167 4.2.4.3 3,7-O,O-Dibenzyl-N-acetylsecolaurolitsine (64) 之製備 168 4.2.4.4 Peracetylsecolaurolitsine (66) 之製備 169 4.2.4.5 1-(2-Acetoxyethyl)-3,7-O,O-diacetyl-4,6-dimethoxyphenanthrene (67) 之製備 170 4.2.4.6 1-(2-Hydroxyethyl)-3,7-dihydroxy-4,6-dimethoxyphenanthrene (68) 之製備 171 4.2.4.7 1-(2-Hydroxyethyl)-3,7-dibenzyloxy-4,6-dimethoxyphenanthrene (69) 之製備 172 4.2.4.8 3-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)ethyl methanesulfonate (70) 之製備 173 4.2.4.9 3-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)propiononitrile (71) 之製備 174 4.2.4.10 3-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)-N,N,N-trimethylpropan-1-aminium iodide (73) 之製備 175 4.2.4.11 3-(3,7-Dihydroxy-4,6-dimethoxyphenanthren-1-yl)-N,N,N-trimethylpropan-1-aminium chloride (74) 之製備 176 4.2.4.12 3,7-Dibenzyloxy-4,6-dimethoxyphenanthrene-1-carbaldehyde (77) 之製備 177 4.2.4.13 2-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)acetaldehyde (78) 之製備 178 4.2.4.14 3,7-Dibenzyloxy-4,6-dimethoxyphenanthrene-1-carboxylic acid (79) 之製備 179 4.2.4.15 1-(2-Hydroxyethyl)-3,7-dihydroxy-4,6-dimethoxy-9,10-dihydrophenanthrene (80) 之製備 181 4.2.4.16 1-(2-Hydroxyethyl)-3,7-dibenzyloxy-4,6-dimethoxy-9,10-dihydrophenanthrene (81) 之製備 181 4.2.4.17 3,7-Dibenzyloxy-4,6-dimethoxy-9,10-dihydrophenanthrene-1-carbaldehyde (83) 之製備 182 4.2.4.18 2-(3,7-Dibenzyloxy-4,6-dimethoxy-9,10-dihydrophenanthren-1-yl)acetaldehyde (84) 之製備 183 4.2.4.19 Peracetyl-9,10-dihydrosecolaurolitsine (85) 之製備 184 4.2.4.20 1-(Hydroxymethyl)-3,7-dibenzyloxy-4,6-dimethoxyphenanthrene (90) 之製備 185 4.2.4.21 2-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)acetonitrile (91) 之製備 186 4.2.4.22 2-(3,7-Dihydroxy-4,6-dimethoxyphenanthren-1-yl)acetic acid (76) 之製備 188 4.2.4.23 3-(3,7-Dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)propanoic acid (92) 之製備 189 4.2.4.24 3-(3,7-Dihydroxy-4,6-dimethoxyphenanthren-1-yl)propanoic acid (93) 之製備 190 4.2.4.25 Ethyl 3-(3,7-dibenzyloxy-4,6-dimethoxyphenanthren-1-yl)propanoate (94) 之製備 191 4.2.4.26 1-(3-Hydroxypropyl)-3,7-dibenzyloxy-4,6-dimethoxyphenanthrene (95) 之製備 192 4.2.4.27 1-(3-Hydroxypropyl)-3,7-dihydroxy-4,6-dimethoxyphenanthrene (96) 之製備 193 4.3 乙醯膽鹼酶抑制活性試驗 194 4.3.1 原理 194 4.3.2 實驗方法 194 4.3.2.1 試劑配製 194 4.3.2.2 乙醯膽鹼酶Km測試 195 4.3.2.3 實驗步驟 196 4.3.2.4 IC50之計算 197 4.4 黃嘌呤氧化酶抑制活性試驗 198 參考資料 199 | |
dc.language.iso | zh-TW | |
dc.title | 第一部分:穗花香苦草、短柄香苦草及香苦草種子化學成分之研究 第二部分:Aporphine及phenanthrene衍生物之製備暨其抗乙醯膽鹼酶與黃嘌呤氧化酶之探討 | zh_TW |
dc.title | Part I Chemical investigation of Hyptis spicigera, H. brevipes, and the seed of H. suaveolens Part II Preparation of aporphine and phenanthrene derivatives as acetylcholinesterase inhibitors and xanthine oxidase inhibitors | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 梁碧惠(Pi-Hui Liang),李安榮(An-Rong Lee),林雲蓮(Yun-Lian Lin),許麗卿(Lih-Ching Hsu),黃偉展(Wei-Jan Huang) | |
dc.subject.keyword | 穗花香苦草,短柄香苦草,香苦草,山粉圓,黃嘌呤氧化酶,阿朴芬類生物鹼,litebamine型生物鹼,phenanthrene型衍生物,乙醯膽鹼酶, | zh_TW |
dc.subject.keyword | Hyptis spicigera,H. brevipes,H. suaveolens seed,xanthine oxidase,aporphine alkaloids,litebamine alkaloids,phenanthrene derivatives,acetylcholinesterase, | en |
dc.relation.page | 360 | |
dc.identifier.doi | 10.6342/NTU202002369 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
dc.date.embargo-lift | 2023-08-04 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0408202014112800.pdf 目前未授權公開取用 | 16.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。